EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte Studie

Adaptive design increased success but does not significantly accelerate confirmatory oncology trials

Sujata Purja iD, Eunyoung Kim iD

JNCI: Journal of the National Cancer Institute · 01.10.2026 · 118 (10) · 1888-1898

DOI: 10.1093/jnci/djag129 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift JNCI: Journal of the National Cancer Institute, online erschienen am 29.04.2026. Verfasst von Sujata Purja und 1 weiteren Autor:innen. Beteiligte Einrichtung: Data Science, Evidence-Based and Clinical Research Laboratory, Department of Health, Social, and Clinical Pharmacy, College of Pharmacy, Chung-Ang Un…. Hauptthemen laut MEDLINE: Breast Neoplasms, Clinical Trials, Phase III as Topic, Lung Neoplasms, Randomized Controlled Trials as Topic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: National Research Foundation of Korea, KHIDI, MICT.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Adaptive designs are increasingly employed to improve trial efficiency; however, their benefits over fixed designs in late-phase oncology trials remain underexplored. We aimed to determine whether adaptive designs in phase 3 cancer trials are associated with primary completion time and primary endpoint success compared with fixed designs.

Methods

This cross-sectional study analyzed phase 3 randomized lung and breast cancer trials initiated between 2000 and 2020 using Aggregate Analysis of ClinicalTrials.gov database (static version downloaded April 15, 2025). Eligible trials had time-to-event primary endpoints and were completed or terminated. Trials were classified as adaptive or nonadaptive based on preplanned design modifications. Associations between trial design and primary completion time were examined using Kaplan–Meier curves and multivariable cause-specific Cox regression, while associations between trial design and primary endpoint success were examined using multivariable logistic regression.

Results

Of 421 eligible trials, 210 employed adaptive designs. Adoption of adaptive designs increased over time, with group-sequential designs being the most common adaptive approach. Adaptive designs showed earlier primary completion, but no statistically significant association was observed after multivariable adjustment. Adaptive trials had higher hazards of early stopping for efficacy or futility and lower hazards of administrative termination. Among 396 trials with available results, 163 achieved primary endpoint success. Adaptive trials had higher odds of success than nonadaptive trials (66.26% vs 33.74%; odds ratio [OR] = 2.363, 95% CI = 1.491 to 3.778; P < .001).

Conclusions

Adaptive designs were associated with higher primary endpoint success but not shorter primary completion time. Given high failure rates in late-phase oncology, adaptive designs may improve efficiency primarily by facilitating data-driven decisions rather than accelerating trial timelines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsClinical Trials, Phase III as TopicLung NeoplasmsRandomized Controlled Trials as TopicResearch DesignFemaleHumansCross-Sectional StudiesEndpoint DeterminationTime Factors

Autor:innen und Institutionen

  • Data Science, Evidence-Based and Clinical Research Laboratory, Department of Health, Social, and Clinical Pharmacy, College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea.
  • Central Research Centre of Epigenome based Platform and Its Application for Drug Development, College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea.
  • Department of Pharmaceutical, Biohealth industry Chung-Ang University, Seoul, 06974, Republic of Korea.
  • Department of Pharmaceutical Regulatory Science, Chung-Ang University, Seoul, 06974, Republic of Korea.

ORCID-Profile: Sujata Purja, Eunyoung Kim

Förderung

  • National Research Foundation of Korea
  • KHIDI
  • MICT

Zitieren

APA

Purja, S., & Kim, E. (2026). Adaptive design increased success but does not significantly accelerate confirmatory oncology trials. JNCI: Journal of the National Cancer Institute, 118(10), 1888-1898. https://doi.org/10.1093/jnci/djag129

Vancouver

Purja S, Kim E. Adaptive design increased success but does not significantly accelerate confirmatory oncology trials. JNCI: Journal of the National Cancer Institute. 2026;118(10):1888-1898. doi:10.1093/jnci/djag129

BibTeX
@article{Purja2026,
  author = {Purja, Sujata and Kim, Eunyoung},
  title = {Adaptive design increased success but does not significantly accelerate confirmatory oncology trials},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2026},
  volume = {118},
  number = {10},
  pages = {1888--1898},
  doi = {10.1093/jnci/djag129}
}
Kostenlos starten →